BioMarin, NASDAQ and BMRN

BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target Raised to $113.00
BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) had its target price upped by UBS Group from $109.00 to $113.00 in a research report report published on Thursday,Benzinga reports. They currently have a buy rating on the biotechnology company’s stock.
Why BioMarin Pharmaceutical (BMRN) Stock Is Trading Up Today
Shares of biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) jumped 9.6% in the pre-market session after the company reported impressive fourth-quarter results, exceeding analysts' sales and EPS estimates.
BioMarin Pharmaceutical (NASDAQ:BMRN) Reports Bullish Q4, Stock Soars
Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, with sales up 15.6% year on year to $747.3 million. The company’s full-year revenue guidance of $3.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript February 19, 2025 BioMarin Pharmaceutical Inc. beats earnings expectations. Reported EPS is $0.64, expectations were $0.54. Operator: Ladies and gentlemen, thank you for standing by and welcome to the BioMarin Pharmaceuticals fourth quarter and full year 2024 conference call.
Wedbush Remains a Buy on BioMarin Pharmaceutical (BMRN)
In a report released today, Yun Zhong from Wedbush maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report), with a price
Why BioMarin Pharmaceutical Stock Zoomed Almost 5% Higher Today
BioMarin Pharmaceutical (NASDAQ: BMRN) was a lively stock in the best way on Thursday following the release of its latest set of quarterly results. Enthusiastic investors traded the company's shares up by nearly 5% in price,
Hosted on MSN3d
BioMarin Q4 Earnings & Sales Top Estimates, Stock Up on Upbeat '25 View
BioMarin Pharmaceutical BMRN reported fourth-quarter adjusted earnings per share of 92 cents, which beat the Zacks Consensus ...
Cantor Fitzgerald Reiterates “Overweight” Rating for BioMarin Pharmaceutical (NASDAQ:BMRN)
BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report)‘s stock had its “overweight” rating reissued by investment analysts ...
Demystifying Biomarin Pharmaceutical: Insights From 8 Analyst Reviews
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $94.25, a high estimate of $126.00, and a low estimate of $70.00. This current ...
BioMarin price target raised to $80 from $78 at Scotiabank
Scotiabank raised the firm’s price target on BioMarin (BMRN) to $80 from $78 and keeps a Sector Perform rating on the shares. The firm is ...
BioMarin: Q4 Earnings Snapshot
SAN RAFAEL, Calif. (AP) — SAN RAFAEL, Calif. (AP) — BioMarin Pharmaceutical Inc. (BMRN) on Wednesday reported fourth-quarter profit of $124.9 million. The San Rafael, California-based company said it ...
What is Zacks Research’s Estimate for BMRN Q3 Earnings?
Zacks Research raised their Q3 2025 earnings estimates for BioMarin Pharmaceutical in a report released on Monday, February ...
BioMarin price target raised to $126 from $122 at Piper Sandler
Piper Sandler raised the firm’s price target on BioMarin (BMRN) to $126 from $122 and keeps an Overweight rating on the shares following a Q4 ...
BioMarin projects 10% revenue growth to $3.1B-$3.2B for 2025, driven by VOXZOGO expansion
Q4 2024 Management View CEO Alexander Hardy emphasized that 2024 marked a year of record growth and profitability for BioMarin, with revenue increasing by 18% year-over-year and non-GAAP diluted EPS ...